Drug intelligence / Profile preview

AVL-101

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

AVL-101 is an orally bioavailable, small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) developed by Avila Therapeutics. It utilizes a covalent bonding mechanism to achieve potent and selective inhibition of BTK, a key signaling protein in B-cell development and activation. By irreversibly binding to the target, AVL-101 aims to "silence" the protein, providing a prolonged duration of action. It was primarily investigated for the treatment of B-cell hematological malignancies, such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (B-CLL).

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on AVL-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVL-101.

Explore the full profile